Sharma Shubham, Mitteaux Jérémie, Pipier Angélique, Pirrotta Marc, Penouilh Marie-José, Monchaud David, Datta Bhaskar
Department of Biological Sciences and Engineering, Indian Institute of Technology Gandhinagar, Gandhinagar, Gujarat, 382055, India.
Institut de Chimie Moléculaire de l'Université de Bourgogne (ICMUB), Université Bourgogne Europe (UBE), CNRS UMR6302, Dijon, 21000, France.
BMC Biol. 2025 Aug 8;23(1):249. doi: 10.1186/s12915-025-02322-8.
Non-coding RNAs (ncRNAs) in human cells constitute a substantial portion of the transcriptome but do not lead to protein synthesis. Among them, long non-coding RNAs (lncRNAs, > 200 nucleotides long) are fascinating in their ability to orchestrate critical cellular functions that govern cell development, differentiation, and metabolism. Therefore, the dysregulation of lncRNAs has been linked with several diseases, chiefly cancers.
We focused here on colorectal cancer (CRC), the second-highest cause of mortalities related to cancer worldwide, and more particularly on three lncRNAs, i.e., LINC01589, MELTF-AS1, and UXT-AS1, known to be dysregulated in CRC. We identified a vulnerability in these lncRNAs that could be exploited from a therapeutic point of view: a part of their sequence folds into a secondary structure referred to as G-quadruplex (G4), which is suspected to play active roles in the lncRNA functions. We demonstrate here that these sequences do fold into G4s both in vitro and in CRC cells, and that these G4s can be modulated using PhpC, a prototype molecule for destabilizing G4s.
We describe an innovative anticancer strategy that fully abides by the rules of chemical biology. We indeed modulate the formation of G4s in cells using ad hoc molecular tools in the aim of disturbing the homeostasis and inner functioning of lncRNAs. By exploiting cellular outcomes, we infer how this pharmacomodulation affects CRC biology and, beyond this, the fate of CRC cells owing to the flawed repertoire of correction and/or compensatory mechanisms in cancer cells.
人类细胞中的非编码RNA(ncRNAs)构成了转录组的很大一部分,但不会导致蛋白质合成。其中,长链非编码RNA(lncRNAs,长度大于200个核苷酸)能够协调控制细胞发育、分化和代谢的关键细胞功能,这一点令人着迷。因此,lncRNAs的失调与多种疾病相关,主要是癌症。
我们在此聚焦于结直肠癌(CRC),它是全球癌症相关死亡的第二大原因,更具体地关注三种已知在CRC中失调的lncRNAs,即LINC01589、MELTF-AS1和UXT-AS1。我们发现了这些lncRNAs中一个从治疗角度可加以利用的弱点:它们的部分序列折叠成一种称为G-四链体(G4)的二级结构,据推测该结构在lncRNA功能中发挥着积极作用。我们在此证明,这些序列在体外和CRC细胞中均能折叠成G4,并且这些G4可以使用PhpC进行调节,PhpC是一种使G4不稳定的原型分子。
我们描述了一种完全遵循化学生物学规则的创新抗癌策略。我们确实使用特制的分子工具在细胞中调节G4的形成,目的是扰乱lncRNAs的稳态和内部功能。通过利用细胞结果,我们推断这种药物调节如何影响CRC生物学,除此之外,由于癌细胞中纠正和/或补偿机制的缺陷库,它还会影响CRC细胞的命运。